ストックスクリーナーアプリを入手
11.17
0.45%
0.05
前日終値:
$11.12
開ける：
$11.08
24時間の取引高:
63,546
Relative Volume:
0.39
時価総額：
$325.97M
収益：
-
当期純損益:
$-35.46M
株価収益率:
-26.48
EPS:
-0.4218
ネットキャッシュフロー:
$-34.00M
1週間 パフォーマンス:
+3.81%
1か月 パフォーマンス:
+7.51%
6か月 パフォーマンス:
+153.29%
1年 パフォーマンス:
-20.95%
1日の値動き範囲:
$10.86
$11.43
1週間の範囲:
$10.42
$11.43
52週間の値動き範囲:
$3.35
$15.25
Contineum Therapeutics Inc Stock (CTNM) Company Profile
名前
Contineum Therapeutics Inc
セクター
電話
(858) 333-5280
住所
3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO
CTNM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CTNM
Contineum Therapeutics Inc
|
11.17 | 324.51M | 0 | -35.46M | -34.00M | -0.4218 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Contineum Therapeutics Inc Stock (CTNM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-13 | 開始されました | Leerink Partners | Outperform |
| 2025-09-25 | 開始されました | Leerink Partners | Outperform |
| 2025-06-20 | 開始されました | William Blair | Outperform |
| 2024-10-22 | 開始されました | Robert W. Baird | Outperform |
| 2024-04-30 | 開始されました | Morgan Stanley | Overweight |
| 2024-04-30 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-04-30 | 開始されました | Stifel | Buy |
すべてを表示
Contineum Therapeutics Inc (CTNM) 最新ニュース
Will Contineum Therapeutics Inc. stock rally after Fed decisionsWeekly Profit Recap & Daily Oversold Stock Bounce Ideas - Newser
Contineum Therapeutics, Inc. $CTNM Shares Purchased by Franklin Resources Inc. - MarketBeat
Critical Survey: BioMarin Pharmaceutical (NASDAQ:BMRN) & Contineum Therapeutics (NASDAQ:CTNM) - Defense World
Aug Volume: How risky is Contineum Therapeutics Inc. stock now2025 Geopolitical Influence & Technical Pattern Recognition Alerts - BỘ NỘI VỤ
Support Test: Why Contineum Therapeutics Inc. stock attracts high net worth investorsMarket Performance Recap & Technical Analysis for Trade Confirmation - moha.gov.vn
CTNMContineum Therapeutics Latest Stock News & Market Updates - Stock Titan
Contineum Therapeutics (NASDAQ:CTNM) Price Target Lowered to $14.00 at Robert W. Baird - Defense World
Contineum Therapeutics (NASDAQ:CTNM) Given New $14.00 Price Target at Robert W. Baird - MarketBeat
Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference - BioSpace
Baird Maintains Contineum Therapeutics (CTNM) Outperform Recommendation - Nasdaq
Contineum MS drug stumbles in mid-stage trial - Indian Pharma Post
CTNM: Analyst Baird Lowers Price Target to $14.00 but Maintains Outperform Rating | CTNM Stock News - GuruFocus
Royal Bank Of Canada Has Lowered Expectations for Contineum Therapeutics (NASDAQ:CTNM) Stock Price - Defense World
Contineum Therapeutics, Inc. Class A (CTNM) Gets a Buy from RBC Capital - The Globe and Mail
RBC Capital Maintains Contineum Therapeutics (CTNM) Outperform Recommendation - Nasdaq
Contineum Shares Fall After Phase 2 PIPE-307 Trial Fails to Meet Efficacy Goals in Multiple Sclerosis - marketscreener.com
Contineum’s MS drug falls short in Phase II trial - Yahoo Finance
Contineum’s PIPE-307 misses in midstage MS study - BioWorld MedTech
Contineum Therapeutics Inc trading resumes - MSN
Contineum Therapeutics' Multiple Sclerosis Trial Disappoints, But Analyst Sees Other Assets Driving Value - Benzinga
Stifel maintains Buy rating on Contineum Therapeutics stock despite MS trial failure - Investing.com Canada
Contineum’s PIPE-307 Fails Phase II MS Trial, Focus Shifts To IPF Candidate - Citeline News & Insights
RBC Capital Lowers Price Target for Contineum Therapeutics (CTNM) | CTNM Stock News - GuruFocus
RBC Capital Lowers Price Target for Contineum Therapeutics (CTNM - GuruFocus
RBC Lowers Price Target on Contineum Therapeutics to $22 From $25, Keeps Outperform, Speculative Risk - MarketScreener
Contineum falls after missing main goals in multiple sclerosis trial - Seeking Alpha
Contineum stock down after MS drug fails in trial - The Pharma Letter
J&J, Contineum Fail ‘Risky’ Mid-Stage Multiple Sclerosis Trial - BioSpace
A look into Contineum Therapeutics Inc (CTNM)’s deeper side - Setenews
Contineum Therapeutics: Undervalued Potential in IPF with PIPE-791 Amidst PIPE-307 Setback - TipRanks
Positive Outlook on Contineum Therapeutics Despite Setbacks, Driven by PIPE-791’s Potential in IPF - TipRanks
A brain biotech’s top drug fails against MS - BioPharma Dive
Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) - BioSpace
Stocks to Watch: Contineum, Gap Inc., Geospace Technologies - 富途牛牛
Optimistic Buy Rating for Contineum Therapeutics Amid Promising PIPE-791 Developments - TipRanks
Contineum’s multiple sclerosis drug fails to meet efficacy endpoints By Investing.com - Investing.com Nigeria
Contineum stock falls after multiple sclerosis drug fails in trial By Investing.com - Investing.com Australia
Contineum Therapeutics reports topline data from its phase 2 Pipe-307 Vista trial for the treatment of relapsing-remitting Multiple Sclerosis - marketscreener.com
Contineum stock falls after multiple sclerosis drug fails in trial - Investing.com
Contineum’s multiple sclerosis drug fails to meet efficacy endpoints - Investing.com
Contineum Therapeutics Reports Phase 2 Trial Results - TipRanks
Contineum Therapeutics, Inc. Reports Topline Data from its Phase 2 PIPE-307 Trial for the Treatment of Relapsing-Remitting Multiple SCLEROSIS - MarketScreener
[8-K] Contineum Therapeutics, Inc. Reports Material Event | CTNM SEC FilingForm 8-K - Stock Titan
Why Contineum Therapeutics Inc. stock could see breakout soon - newser.com
Real time social sentiment graph for Contineum Therapeutics Inc.2025 Price Momentum & Fast Exit Strategy with Risk Control - newser.com
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Morgan Stanley Raises Price Target on Contineum Therapeutics to $23 From $21, Keeps Overweight Rating - MarketScreener
How Contineum Therapeutics Inc. stock reacts to inflationary pressures2025 Risk Factors & Expert Curated Trade Setups - newser.com
Will Contineum Therapeutics Inc. stock benefit from automationQuarterly Portfolio Review & Proven Capital Preservation Methods - newser.com
Contineum Therapeutics Inc (CTNM) 財務データ
収益
当期純利益
現金流量
EPS
1.10%
1.10%
大文字化:
|
ボリューム (24 時間):